Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.

Alice B. Gottlieb*, Kenneth B. Gordon, Mark G. Lebwohl, Ivor Caro, Patricia A. Walicke, Nicole Li, Craig L. Leonardi

*Corresponding author for this work

Research output: Contribution to journalArticle

79 Scopus citations

Abstract

Agents that safely provide long-term control of psoriasis are needed. To determine the safety and efficacy of extended efalizumab therapy, 339 patients with moderate to severe chronic plaque psoriasis received 2 mg/kg subcutaneous (SC) efalizumab weekly for 12 weeks. At Week 12, 290 patients who achieved > or =50% Psoriasis Area and Severity Index (PASI-50) improvement or a static Physician's Global Assessment grading of "mild," "minimal," or "clear" entered maintenance treatment with weekly SC efalizumab. At Week 12, 82%, 41%, and 13% of 339 patients achieved a PASI-50, PASI-75, and PASI-90 response, respectively. At 15 months, 65%, 50%, and 25% of patients achieved a PASI-50, PASI-75, and PASI-90 response, respectively (intent-to-treat, n = 339). The incidence of adverse events did not increase over time, and no new common adverse events were reported. The majority of patients experienced sustained efficacy with no increase in toxicity. This study is planned to continue; patients will receive up to 36 months of continuous efalizumab.

Original languageEnglish (US)
Pages (from-to)614-624
Number of pages11
JournalJournal of drugs in dermatology : JDD
Volume3
Issue number6
StatePublished - Jan 1 2004

ASJC Scopus subject areas

  • Dermatology

Fingerprint Dive into the research topics of 'Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.'. Together they form a unique fingerprint.

  • Cite this

    Gottlieb, A. B., Gordon, K. B., Lebwohl, M. G., Caro, I., Walicke, P. A., Li, N., & Leonardi, C. L. (2004). Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. Journal of drugs in dermatology : JDD, 3(6), 614-624.